LEUCOMYCIN A1

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C40H67NO14
Molecular Weight	785.9583
Optical Activity	UNSPECIFIED
Defined Stereocenters	16 / 16
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]2(O[C@H]1[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]1OC)O[C@H](C)[C@@]([H])(O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C

InChI

InChIKey=IEMDOFXTVAPVLX-YWQHLDGFSA-N

InChI=1S/C40H67NO14/c1-22(2)18-30(45)53-38-26(6)51-32(21-40(38,7)48)54-35-25(5)52-39(34(47)33(35)41(8)9)55-36-27(16-17-42)19-23(3)28(43)15-13-11-12-14-24(4)50-31(46)20-29(44)37(36)49-10/h11-13,15,17,22-29,32-39,43-44,47-48H,14,16,18-21H2,1-10H3/b12-11+,15-13+/t23-,24-,25-,26+,27+,28+,29-,32+,33-,34-,35-,36+,37+,38+,39+,40-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.antimicrobe.org/drugpopup/josamycin.htm
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68015570 | https://www.ncbi.nlm.nih.gov/pubmed/4012

Josamycin is a macrolide antibiotic produced by Streptomyces narbonensis var. josamyceticus. Macrolides are inhibitors of protein synthesis. They impair the elongation cycle of the peptidyl chain by specifically binding to the 50S subunit of the ribosome. Josamycin has antimicrobial activity against a wide spectrum of pathogens. It is similar to erythromycin, but does not induce macrolide resistance in staphylococci and appears to have a lower incidence of gastrointestinal side effects. Josamycin is under investigation in US.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial 70S ribosome 179 Target ID: CHEMBL2363135 Sources: http://www.antimicrobe.org/drugpopup/josamycin.htm	Binding Agent 1064		5.5 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Bronchitis 51 Sources: http://www.antimicrobe.org/drugpopup/josamycin.htm	Curative	Approved 8429	Josamycin Approved Use Bronchitis, Mediterranean spotted fever, Mycoplasma pneumonia.
Mediterranean spotted fever 2 Sources: http://www.antimicrobe.org/drugpopup/josamycin.htm	Curative	Approved 8429	Josamycin Approved Use Bronchitis, Mediterranean spotted fever, Mycoplasma pneumonia.
Mycoplasma pneumonia 2 Sources: http://www.antimicrobe.org/drugpopup/josamycin.htm	Curative	Approved 8429	Josamycin Approved Use Bronchitis, Mediterranean spotted fever, Mycoplasma pneumonia.

PubMed

Title	Date	PubMed
Screening for new compounds with antiherpes activity.	1984 Oct	6517562

Patents

Sample Use Guides

In Vivo Use Guide

Bronchitis: 500 mg three times daily for up to 14 days. Mediterranean spotted fever: 1 g every 8 hours for 5 days. Mycoplasma pneumonia: 2 g per day (in four equally divided doses) for 7 days.

Route of Administration: Oral

In Vitro Use Guide

The MIC values for josamycin were: 0.007-0.25 ug/ml (Mycoplasma pneumoniae), 0.007-0.25 ug/ml (Streptococcus pneumoniae), 0.06-0.5 ug/ml (Streptococcus pyogenes), 0.5-2.0 ug/ml (Staphylococcus aureus), 0.5-8.0 ug/ml (Haemophilus influenzae), 0.125->8 ug/ml (Bacteroides fiagilis).

Name

Type

Language

LEUCOMYCIN A1

Common Name

English

3-O-DEACETYLJOSAMYCIN

Common Name

English

3-DEACETYLJOSAMYCIN

Common Name

English

TURIMYCIN H5

Common Name

English

LEUCOMYCIN A1 [MI]

Common Name

English

LEUCOMYCIN V, 4B-(3-METHYLBUTANOATE)

Common Name

English

LEUCOMYCIN V 4-ISOVALERATE

Common Name

English

KITASAMYCIN A1

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID50101646